|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.53 USD | -1.56% |
|
-1.56% | -39.76% |
| 05-20 | Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index | CI |
| 05-17 | First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc | CI |
First Wave BioPharma, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 14.63 million compared to USD 58.54 million a year ago. Basic loss per share applicable to common shareholders was USD 21 compared to USD 1,988.53 a year ago.
Diluted loss per share applicable to common shareholders was USD 21 compared to USD 1,988.53 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -39.76% | 6.26M | |
| +55.70% | 59.34B | |
| +41.08% | 40.24B | |
| -5.39% | 39.88B | |
| -5.56% | 28.55B | |
| +16.46% | 27.26B | |
| -20.56% | 19.23B | |
| +33.03% | 12.61B | |
| +25.85% | 12.28B | |
| +2.72% | 12.49B |
ENTERO THERAPEUTICS, INC. 
